TOKYO, Apr 27 (Pulse News Wire) – Astellas Pharma Inc. (4503.T) reported revenue of ¥301 billion for the fourth quarter of fiscal year 2026, marking a 14% increase compared to the same period last year.
Operating profit reached ¥168 billion, reflecting strong performance across key markets. Sales growth was driven by increased demand for products such as XTANDI and PADCEV in major regions including the United States, Japan, and Europe. In the United States, sales grew significantly with PADCEV contributing ¥857 million, up from ¥716 million in the previous year.
Similarly, in Japan, XTANDI saw a substantial rise to ¥648 million from ¥579 million. European markets also showed robust growth, with XTANDI leading the way at €¥1.665 billion, up from €¥1.602 billion. Looking ahead, the company expects continued momentum in its core product lines and ongoing investment in research and development to sustain growth.
🟢 Confidence: High AI-translated content.